OBJECTIVE To assess whether markers of systemic and atrial inflammation are associated with incident AF in the general population.
troversial. Evidence has been derived from histologic studies of atrial tissue in patients with AF demonstrating inflammatory infiltrates as well as from a number of epidemiologic studies reporting an association between circulatory inflammation markers, such as C-reactive protein (CRP), osteoprotegerin (OPG), and soluble intercellular adhesion molecule 1 (ICAM-1), with incident AF. [5] [6] [7] [8] A potential role of vascular cell adhesion molecule 1 (VCAM-1) in the development and maintenance of AF has been suggested. As a mediator of leukocyte trafficking, VCAM-1 is relevant to various cardiac diseases, including congestive heart failure as well as ischemic and rheumatic heart disease. [9] [10] [11] [12] An intriguing human atrial tissue culture model and an in vivo pig model demonstrated that local VCAM-1 expression is upregulated during rapid atrial pacing and potentially contributes to an inflammatory and prothrombotic environment within atrial tissue, which was termed "endocardial remodeling." 13, 14 Whether inflammation related to AF is primarily a systemic or localized phenomenon is still debated.
In this study, we aimed to investigate the association of 13 baseline inflammation markers with incident AF in the longterm, prospective, population-based Bruneck Study, [15] [16] [17] carefully characterize this association, and replicate key findings in another large cohort from the same geographic region.
Methods

Study Population
The Bruneck Study is a prospective, population-based survey on cardiovascular disease, which started in 1990. [15] [16] [17] An ageand sex-stratified random sample of 1000 individuals was drawn from all residents aged 40 to 79 years (n = 4739) living in Bruneck, northern Italy. The response rate was 93.6%, with blood samples for assessment of soluble VCAM-1 (sVCAM-1) available in 909 individuals. Reevaluations were scheduled every 5 years (1995, 2000, 2005, and 2010 ). Follow-up was 100% complete for clinical end points. The study protocol was reviewed and approved by the University of Verona and Bolzano (Südtiroler Sanitätsbetrieb), and all participants provided written informed consent before entering the study. There was no financial compensation. All characteristics of the participants were assessed by means of standard procedures described previously [15] [16] [17] and detailed in the eMethods in the Supplement.
Ascertainment of AF
Atrial fibrillation was assessed according to the Minnesota coding system (Minnesota code 8.3) 18 by 2 cardiologists (G.E. and M.O.) from electrocardiograms (ECGs). 17 Participants underwent a 12-lead ECG at baseline and during the 4 follow-up examinations and were asked whether they had a history of AF. In addition, Bruneck Hospital provided all ECGs and 24-hour Holter monitoring recordings performed on the participants between 1990 and 2010 (outside the study protocol), and we also had information on ECGs recorded at the general practitioners' offices. Overall, a mean of 334 standard ECGs per 1000 person-years were available for review. In addition, 39 participants had 1 or more 24-hour Holter monitoring recordings. Moreover, we searched medical records and discharge letters from the Bruneck Hospital back to 1980 and obtained additional records from the general practitioners if the participant reported AF. Of 117 incident AF cases, 28 (23.9%) participants had AF newly detected at scheduled follow-up study visits and 89 (76.1%) cases were determined through clinical records. The type of AF was classified as paroxysmal (selfterminating) or persistent (lasting >7 days or requiring cardioversion). The date of first diagnosis of AF was documented. AF occurring transiently in the context of acute coronary syndrome or cardiac surgery was not included.
Ascertainment of Ischemic AF-Related Stroke
Ischemic stroke and transient ischemic attack were classified according to the criteria of the National Survey of Stroke.
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Ischemic AF-related stroke was defined as follows: (1) known (prediagnosed) AF or de novo AF ascertained as part of the diagnostic workup of the stroke event and (2) absence of another, more obvious, cause of stroke (eg, cranial vessel dissection or ipsilateral high-grade carotid stenosis with arterioarterial stroke pattern). Ischemic stroke was determined by interview during study visits, the thorough clinical examinations performed as part of the study protocol, and careful review of databases from Bruneck Hospital. [15] [16] [17] Self-report of ischemic stroke was confirmed by medical records.
Laboratory Methods
Venous blood samples were drawn after an overnight fast and 12 hours of abstinence from smoking. All participants had levels of sVCAM-1 measured in duplicate using a commercially available enzyme-linked immunosorbent assay kit (Bender MedSystems). Intra-assay and interassay coefficients of variation were 4.8% and 11.2%, respectively. 16 Measurements were
Key Points
Question Are markers of systemic and atrial inflammation associated with incident atrial fibrillation in the general population?
Findings In this population-based cohort study, level of soluble vascular cell adhesion molecule 1 emerged as the only inflammation marker significantly associated with incident atrial fibrillation in a population-based cohort study. The key association was of a dose-response type with considerable strength and was successfully replicated in a second independent cohort.
Meanings Atrial inflammation as reflected by soluble vascular cell adhesion molecule 1 may be more relevant in atrial fibrillation than systemic inflammation.
: matrix metalloproteinase 9, metalloproteinase inhibitor 1, monocyte chemoattractant protein-1, P-selectin, fibrinogen, OPG, receptor activator of nuclear factor-κB ligand, highsensitivity CRP, adiponectin, leptin, ICAM-1, and E-selectin. In addition, 75 markers of inflammation, immune activation, or endothelial dysfunction markers were recently determined in samples collected during the 2000 follow-up by proximity extension assay 20 (eMethods in the Supplement). Nterminal pro-B-type natriuretic peptide (NT-proBNP) was measured with a validated, commercially available immunoassay (Elecsys ProBNP; Roche Diagnostics) using established methodology.
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Replication Cohort
The Salzburg Atherosclerosis Prevention Program in Subjects at High Individual Risk (SAPHIR) study is a prospective cohort study conducted in 1770 healthy, unrelated individuals (663 women and 1107 men aged 39-67 years) who were recruited by health-screening programs in large companies in and around the city of Salzburg, Austria. 22 The cohort was first ex- 
Statistical Analysis
Continuous variables are presented as means (SDs) and dichotomous variables are reported as percentages. Personyears of follow-up for each participant were accrued from the 1990 baseline until diagnosis of AF, death, or October 1, 2010, whichever came first. In an exploratory approach, the crude as well as age-and sex-adjusted association of 13 baseline inflammation markers with incident AF was examined using Cox proportional hazard models. Owing to skewed distributions, inflammation markers were log e transformed for analysis. The proportional hazard assumption was tested and confirmed using Schoenfeld residuals for all variables in all models. Potential nonlinear associations with incident AF were examined by fitting penalized splines with 3 df.
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In this first exploratory step, only sVCAM-1 emerged as significantly associated with incident AF. This association was further elaborated in multivariable analysis adjusted for age, sex, body mass index, smoking, alcohol consumption, hypertension, NT-proBNP, and high-sensitivity cardiac troponin T (model 1), plus diabetes, glomerular filtration rate, highsensitivity CRP, and atherosclerosis (model 2). Sensitivity analyses were additionally adjusted for heart failure, total thyroxine level, and socioeconomic status, or PR interval and P axis, or angiotensin-converting-enzyme inhibitor and diuretic therapy, or excluded the first 5 years of follow-up. We defined socioeconomic status on a 3-category scale (low, medium, or high) on the basis of information about occupational status and educational level of the person with the highest income in the household. High socioeconomic status was assumed if the participant had 12 or more years of education or an occupation with an average monthly income of $2000 or more (baseline salary before tax). Low socioeconomic status was defined by 8 years or less of education or an average monthly income of $1000 or lower.
Moreover, the association between sVCAM-1 and newonset AF was assessed in various subgroups. To further substantiate the concept that local atrial inflammation reflected by sVCAM-1 is more relevant than systemic inflammation, 75 additional markers of inflammation, immune activation, or endothelial dysfunction were measured by proximity extension assay (samples collected in 2000 with a follow-up from 2000 to 2010) and examined in the context of incident AF. To compare the strength of association of sVCAM-1 with incident AF with that of a broadly accepted and replicated risk predictorofAF, 24 multivariable hazard ratio (HR) associated with a 1-SD higher NT-proBNP level was calculated (adjusted for the covariates as model 2). Finally, a case-control sample nested within the SAPHIR study was used for replication purposes (eMethods in the Supplement). All reported probability values were 2-sided. In Table 1 and Table 2 and eTable 1 in the Supplement, Bonferronicorrected P values were calculated to account for multiple testing. Results were considered statistically significant at a P <.05 level. All calculations were performed using SPSS, version 20.0 (IBM Corp); R, version 3. 
Results
Of the 909 participants in the Bruneck Study (mean [SD] age, 58.8 [11.4] years; 448 [49.3%] women), 29 (3.2%) had prevalent AF. After exclusion of prevalent AF cases, 880 individuals formed the study population for the longitudinal analysis. In the 20-year follow-up period, 117 (13.3%) participants developed AF (incidence rate, 8.2; 95% CI, 6.8-9.6 per 1000 person-years); 44 (5.0%) had paroxysmal AF during the entire follow-up, and 73 (8.3%) progressed to persistent AF. Table 1 reports the association between baseline inflammation markers and incident AF. In univariable analyses, sV-CAM-1 and OPG were significantly associated with incident AF when corrected for multiple testing. After adjustment for age and sex, this association remained significant for sVCAM-1 only. Median (interquartile range [IQR]) baseline sVCAM-1 level was 615.6 ng/mL (501.0-805.1 mg/mL). Table 3 depicts baseline characteristics by low, middle, and high sVCAM-1 level groups (tertile groups). Significant and mostly small quantitative differences were obtained for age, glucose, total thyroxine, highsensitivity CRP, NT-proBNP, high-sensitivity cardiac troponin T, and high-density and low-density lipoprotein cholesterol levels, PR interval and P axis in the baseline ECG; as well as for the frequency of diabetes across sVCAM-1 categories. The incidence of AF was 4.4 (range, 2.7-6.3) per 1000 person-years in the low compared with 9.5 (range, 7.0-12.4) in the middle sVCAM-1 group and 11.4 (range, 8.5-14.5) in the high sVCAM-1 group. In Cox proportional hazards models adjusted for age and sex, sVCAM-1 was significantly associated with incident AF (HR for a 1-SD higher sVCAM-1, 1.36; 95% CI, 1.13-1.64; Bonferroni-corrected P = .02). Results remained similar with additional adjustment for other risk predictors of AF, angiotensin-converting enzyme inhibitor and diuretic therapy, or ECG variables, and after exclusion of the first 5 years of follow-up ( Table 2 ). The use of penalized splines indicated an adequate fit of a linear dose-response association (eFigure 1 in the Supplement). The association between sVCAM-1 and newonset AF was robust in various subgroups, including individuals with and without heart failure, hypertension, and atherosclerosis ( Figure) . The strength of association was at least as high as that obtained for NT-proBNP (multivariable HR for a 1-SD higher NT-proBNP level, 1.15; 95% CI, 1.04-1.26). As anticipated, all other baseline markers of inflammation were not associated with AF, and this extended to 75 markers of inflammation, immune activation, or endothelial dysfunction measured from samples of the 2000 evaluation of the Bruneck Study (eTable 1 in the Supplement).
In the SAPHIR study, 5 of 1770 participants (0.3%) had a diagnosis of AF at baseline. In a nested case-control analysis considering 60 individuals with new-onset AF (14 years' median follow-up) and 114 controls, the sVCAM-1 level was significantly associated with future AF (conditional logistic re- Abbreviations: AF, atrial fibrillation; HR, hazard ratio; sVCAM-1, soluble vascular cell adhesion molecule 1.
a Bonferroni-corrected P value.
b Adjusted for age (years), sex, smoking (0 vs 1), alcohol consumption (grams per day), hypertension (0 vs 1), log e transformed N-terminal pro-B-type natriuretic peptide (picograms per milliliter), and high-sensitivity cardiac troponin T level (undetectable vs tertiles of detectable).
c Additionally adjusted for diabetes (0 vs 1), glomerular filtration rate (milliliters per minute), log e transformed high-sensitivity C-reactive protein (milligrams per liter), and atherosclerosis (0 vs 1).
d Multivariable model 2, plus heart failure (New York Heart Association classes 1-4 vs 0), total thyroxine level (micrograms per deciliter), and socioeconomic status (high, medium, and low).
e Multivariable model 2, plus PR interval (milliseconds), and P axis (Յ30°vs >30°).
f Multivariable model 2, plus angiotensin-converting-enzyme inhibitor therapy (0 vs 1) and diuretic therapy (0 vs 1). Numbers of events and total participants were 117 and 880, respectively. Markers were log e -transformed for analysis and HRs are given for a 1-SD higher concentration in each marker.
b Protein order is arranged by descending significance in unadjusted models. gression: age-and sex-adjusted and multivariable odds ratio (OR) for a 1-SD higher sVCAM-1 level, 1.91; 95% CI, 1.24-2.96; and 2.59; 95% CI, 1.45-4.60; P = .003 and P = .001, respectively). Baseline characteristics of participants in the SAPHIR study are summarized in eTable 2 in the Supplement. Our study yielded preliminary evidence for an association between the level of sVCAM-1 and ischemic AF-associated stroke in the Bruneck Study (n = 24; multivariable HR for a 1-SD higher sVCAM-1 level, 1.54; 95% CI, 1.01-2.35; P = .048), but not ischemic stroke of other etiology (n = 77; multivariable HR for a 1-SD higher sVCAM-1 level, 0.85; 95% CI, 0.66-1.09; P =.20)( Table 4) . Participants with incident ischemic AF-related stroke were significantly older and had higher median NT-proBNP levels than did those with non-AF ischemic-related stroke (mean [SD] No other significant differences in clinical characteristics were found between these 2 groups. The incidence rate was 1.3 (95% CI, 0.9-2.0) per 1000 person-years for AF-related ischemic stroke and 4.4 (95% CI, 3.5-5.5) per 1000 person-years for non-AF-related ischemic stroke. 
Discussion
In an exploratory approach to identify inflammation markers relevant for the occurrence of AF in the general community, sVCAM-1 was the only one significantly associated with longterm risk of AF. The association was of a dose-response type and considerable strength, independent of a large number of clinical and laboratory characteristics, and persisted in various subgroups, including individuals with and without heart failure, hypertension, or atherosclerosis ( Figure) . This key finding was successfully replicated in the SAPHIR study. Being a member of the immunoglobulin superfamily, VCAM-1 is a cell surface protein and expressed by several cell types, especially endothelial cells, but also macrophages, smooth muscle, and dendritic cells. 8, 9 ,25 Soluble forms of VCAM-1 arise from excess surface expression or increased shedding. In addition, VCAM-1 is a key player in the adhesion and transmigration of leukocytes from circulation into surrounding tissue and thus contributes to tissue inflammation (eFigure 2 in the Supplement). Although only low levels are expressed on resting endothelium and endocardium, marked upregulation of VCAM-1 is elicited by various stress conditions. In a number of human heart diseases, reactive oxygen species and hemodynamic factors have been shown to enhance cardiac VCAM-1 expression, 12 ,26 and subsequent cell infiltration and inflammation in heart tissue gives rise to sustained cardiac remodeling, fibrosis, and dysfunction. 4 Accumulating evidence suggests that atrial remodeling is involved in the pathophysiology of AF, and it is tempting to speculate that VCAM-1 in circulation partly reflects local endocardial activation. A 2-fold increase in endocardial VCAM-1 expression was found in patients with paroxysmal and persistent AF. 13 Furthermore, prominent atrial upregulation of VCAM-1 was observed during rapid atrial pacing in in vitro and in vivo experiments. 13 Studies showed that angiotensin II receptor blockers reduce the occurrence of AF and downregulation of adhesion molecules within the atrium was proposed as a potential underlying mechanism. 13, 27 In epidemiologic studies, levels of sVCAM-1 were associated with the presence of AF 14, 28 and highest in patients with left atrial appendage thrombi. 14 To our knowledge, the only prospective study so far to assess the association of VCAM-1 with new-onset AF was conducted in patients with coronary artery disease undergoing cardiac bypass surgery
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; the findings demonstrated that high sVCAM-1 level predicts postoperative AF manifestation.
In an exploratory analysis within the Framingham study, 7 OPG (but not 11 other markers of inflammation) was significantly associated with incident AF (multivariable HR, 1.30; 95% CI, 1.08-1.65; P = .006). Our study also yielded a significant association between OPG and AF in univariable analysis; however, the significance was lost after adjustment for age given a particularly strong correlation between age and OPG (r = 0.52).
Whereas the Women's Health Study reported a weak but significant association between levels of ICAM-1 and incident AF (multivariable HR, 1.11; 95% CI, 1.02-1.20; P = .02), 6 the Framingham Study 7 and our study found no such association.
Several studies observed an association between CRP and incident AF, 5, 6, 30 but results from the Framingham Study were inconsistent 7,31 and our study and other recent studies yielded no association with adjustment for standard AF risk factors.
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Negative findings in the Bruneck Study extend to a large number of markers of systemic inflammation and immune activation (eTable 1 in the Supplement) measured by a custommade proteomics chip that accords with recent findings in 2 Swedish studies using the same chip. 32,33 Overall, current epidemiologic evidence supporting a link between systemic inflammation and AF is weak. The present study is supportive of the emerging concept that local endocardial activation and remodeling is more relevant. Endocardial VCAM-1 expression has been reported to promote thrombogenicity and left atrial appendage clot formation. 13, 14, 34 Epidemiologic evidence on this finding, however, is inconsistent, with 1 study demonstrating an association between sVCAM-1 levels and cardiovascular events in patients with AF 35 and another showing no such association.
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Both studies relied on hospital-based series of patients with AF. Our study adds new data to this controversy and demonstrated a significant association between sVCAM-1 and AF-associated ischemic stroke but not for ischemic stroke of other cause in the general population (Table 4) .
Strengths and Limitations
Strengths of our study are the well-characterized, communitybased cohort with a more than 90% participation rate, longterm follow-up, and rigorous assessment of a large number of clinical and laboratory characteristics. In addition, we were able to replicate key findings in an independent populationderived cohort using the same sVCAM-1 assay. Some limitations have to be mentioned as well. Detection of paroxysmal AF remains a diagnostic challenge. In the near future, systematic long-term recording of AF will become a reality in population-based studies given the recent development of easy-touse, noninvasive cardiac monitors (eg, external loop recorders). Such recording, however, was not feasible in the time period of the present study . Notwithstanding, the Bruneck Study ranks among the prospective population studies with the most thorough ascertainment of AF relying on a mean of 334 ECGs per 1000 person-years. We measured sV-CAM-1 and other inflammation markers only once at baseline in the Bruneck Study. Serial measurements would have better accounted for within-person fluctuations in inflammatory marker levels over time. In the SAPHIR study, consideration of sVCAM-1 levels measured both at baseline and during follow-up further enhanced predictive accuracy.
Conclusions
We found that sVCAM-1 levels, but not markers of systemic inflammation, are significantly and independently associated with incident AF. Although causality cannot be firmly established from observational studies, a causal interpretation between VCAM-1 and AF is favored by several characteristics of the association (Hill's criteria of causation 37 ) including its considerable magnitude and dose-response type, temporality, consistency in various subgroups, and replication in a second independent cohort. Furthermore, the association is biologically plausible and coherent with previous animal and clinical investigations. Our data add to the preliminary evidence that VCAM-1 is involved in atrial remodeling and may well assist in improving AF risk prediction and in selecting the right individuals for intensified AF screening (eg, implantable loop recorder) among patients with ischemic stroke of undetermined origin. 38 Further studies are required to elaborate findings toward these clinical applications. milliseconds) in lead V1 multiplied by the absolute value of its amplitude (µV), was an average of three consecutive cardiac cycles measured manually by two observers.
Prolonged PR interval and corrected QT interval, P wave axis <30° and high values of Pwave terminal force have been associated with atrial abnormality in previous studies [6] [7] [8] [9] .
Myocardial infarction was deemed confirmed when World Health Organization criteria for definite disease status were met 10 . Symptoms suggestive of heart failure were classified using the New York Heart Association classification 11 . Laboratory parameters were measured in baseline samples using standard procedures, as described previously [1] [2] [3] [4] [5] . High-sensitivity cardiac troponin T (hs-cTnT)
was assessed using highly sensitive reagents on an Elecsys® 2010 analyser (Roche Diagnostics, Burgess Hill, UK) 13 . Values of hs-cTnT were categorized into groups of the Cardiovascular Health Study 14 . Other markers of inflammation, immune activation, or endothelial dysfunction were determined in samples collected during the 2000 follow-up
by Proximity Extension Assay (PEA) 15 , using Proseek Multiplex CVD I 96x96 and Proseek
Multiplex Inflammation I 96x96 reagents kits (Olink Bioscience, Uppsala, Sweden). Each of these assays yielded 92 protein measurements. Of 26 proteins that were measured in both assays only measurements from the Inflammation assay were considered, 3 proteins were discarded because they had already been measured in 1990, and 23 proteins were discarded because they had more than 50% nondetects. This resulted in 132 candidate proteins, from which proteins potentially relevant to inflammation, immune activation, or endothelial dysfunction were selected as those annotated with GO terms that were partially matched by any of the character strings "inflamm", "immun", or "endothel", for a final set of 75 proteins measured in 2000. All variables were log e -transformed and standardised to unit variance. 
Methodological details of the SAPHIR
